NVDA vs LLY
NVIDIA Corporation vs Eli Lilly and Company · Updated Nov 13, 2026
NVDA — 10 winsLLY — 13 wins
Price Performance
NVDA -11.06%LLY +39.54%
Performance
| NVDA | LLY | |
|---|---|---|
| 1 Month | -25.68% | +18.81% |
| 3 Months | -26.95% | +21.69% |
| 6 Months | -30.23% | +42.66% |
| YTD | -11.81% | +33.64% |
| 1 Year | -14.85% | +45.27% |
| 3 Year | +261.78% | +216.92% |
| 5 Year | +1200.88% | +590.20% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVDA | -12.0% | +34.8% | +178.8% | +245.9% | -51.5% | +124.3% | +117.7% | +72.4% | -32.9% | +89.8% | +229.9% | +63.7% |
| LLY | +32.1% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
Valuation
| NVDA | LLY | |
|---|---|---|
| P/E Ratio | 33.57 | 51.02 |
| Forward P/E | 12.56 | 24.06 |
| PEG Ratio | 1.20 | 1.77 |
| P/S Ratio | 20.27 | 18.72 |
| P/B Ratio | 27.82 | 43.35 |
| EV/EBITDA | 30.28 | 41.56 |
Financials
| NVDA | LLY | |
|---|---|---|
| EPS (TTM) | $4.90 | $28.15 |
| Gross Margin | +75.00% | +78.98% |
| Operating Margin | +65.02% | +46.44% |
| Net Margin | +63.06% | +37.36% |
| ROE | +76.33% | +81.01% |
| ROA | +58.06% | +21.68% |
| Debt/Equity | 0.07 | 1.39 |
Growth
| NVDA | LLY | |
|---|---|---|
| Revenue Growth YoY | +73.21% | +55.55% |
| Revenue Growth QoQ | +19.51% | +2.63% |
| EPS Growth YoY | +97.75% | +169.94% |
| EPS Growth QoQ | +35.38% | +11.77% |
Technical
| NVDA | LLY | |
|---|---|---|
| RSI (14) | 23.96 | 70.29 |
| % From 20-Day SMA | -18.28% | +6.63% |
| % From 50-Day SMA | -23.84% | +16.25% |
| % From 200-Day SMA | -19.51% | +29.72% |
| % From 52-Week High | -32.42% | -1.63% |
| % From 52-Week Low | +10.53% | +68.86% |
Analyst Ratings
NVDA
Buy(63 analysts)
Strong SellHoldStrong Buy
Price Target
$339.17
+81.09% upside
LLY
Buy(35 analysts)
Strong SellHoldStrong Buy
Price Target
$1445.12
+6.18% upside
Overview
| NVDA | LLY | |
|---|---|---|
| Sector | Technology | Healthcare |
| Industry | Semiconductors | Drug Manufacturers - General |
| Exchange | NASDAQ | NYSE |
| Market Cap | $4.38T | $1.35T |
| Shares Outstanding | 24.10B | 940.7M |
| Avg Volume (10D) | 290.74M | 3.44M |
| Dividend Yield | 0.15% | 0.47% |
Frequently Asked Questions
Is NVDA or LLY a better buy right now?
Based on 23 comparable metrics, LLY leads in 13 categories while NVDA leads in 10. LLY has a consensus analyst rating with 35 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, NVDA or LLY?
Over the past year, NVDA returned -14.85% compared to LLY's +45.27%. In the short term (1 month), NVDA returned -25.68% vs LLY's +18.81%.
Is NVDA or LLY more expensive?
NVDA trades at a P/E of 33.57 compared to LLY's 51.02. On a price-to-sales basis, NVDA trades at 20.27x vs LLY's 18.72x. Forward P/E: NVDA at 12.56 vs LLY at 24.06.
Which stock has higher growth, NVDA or LLY?
NVDA's revenue grew +73.21% year-over-year compared to LLY's +55.55%. EPS growth: NVDA at +97.75% vs LLY at +169.94%.
Do NVDA and LLY pay dividends?
NVDA pays a dividend with a yield of 0.15%. LLY pays a dividend with a yield of 0.47%.
Which stock do analysts prefer, NVDA or LLY?
NVDA has 63 analysts with a target price of $339.17 (+81.09% upside). LLY has 35 analysts with a target of $1445.12 (+6.18% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.